Approval to Escalate Dosing in Kidney Disease Clinical Trial
Filed with ASX · · 4 pages · English
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- Approval to Progress Kidney Disease Trial to Next Stage
- Fourth Drug Program Progressing to Human Trials
- FDA Alignment on Registrational Trial Design RP11 Program
- SRC Approves Dose Escalation in ADOA Clinical Trial
- Approval to Escalate Dosing in Kidney Disease Trial
Later from PYC Therapeutics
- Appendix 4E
- PKD Program - Presentation of Safety Data at ANZSN
- ADOA Program - Presentation of Clinical Data at NOSA 2025
- Change of Managing Director
- Correction to Trading Halt Request
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics